biology-products/kodak-image-station-4000mm-digital-imaging-system-from-molecular-imaging-systems--carestream-health--inc---28formerly-kodak-molecular-imaging-systems--428-1/;msg90356

Breaking Biology Technology:YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4

[0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES [0] Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner [0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain [0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea

Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3 Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2 Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 1 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 2 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 3 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 4 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 5 West to Present at Two Upcoming Investor Conferences 56960 1 West to Present at Two Upcoming Investor Conferences 56960 2 Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 1 Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 2

[0] Dynatronics Receives 180-Day NASDAQ Extension [0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug [0] Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign